Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Dirty-appearing white matter in multiple sclerosis: preliminary observations of myelin phospholipid and axonal loss.

Moore GR, Laule C, Mackay A, Leung E, Li DK, Zhao G, Traboulsee AL, Paty DW.

J Neurol. 2008 Nov;255(11):1802-11. doi: 10.1007/s00415-008-0002-z. Epub 2008 Sep 24.

PMID:
18821049
2.

Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology.

Laule C, Leung E, Lis DK, Traboulsee AL, Paty DW, MacKay AL, Moore GR.

Mult Scler. 2006 Dec;12(6):747-53.

PMID:
17263002
3.

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group.

Neurology. 2006 Mar 28;66(6):894-900.

PMID:
16567708
4.

Biliverdin reductase, a major physiologic cytoprotectant, suppresses experimental autoimmune encephalomyelitis.

Liu Y, Liu J, Tetzlaff W, Paty DW, Cynader MS.

Free Radic Biol Med. 2006 Mar 15;40(6):960-7. Epub 2005 Oct 17.

PMID:
16540391
5.

Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.

Simon JH, Li D, Traboulsee A, Coyle PK, Arnold DL, Barkhof F, Frank JA, Grossman R, Paty DW, Radue EW, Wolinsky JS.

AJNR Am J Neuroradiol. 2006 Feb;27(2):455-61. No abstract available.

6.

Treatment optimization in multiple sclerosis.

Freedman MS, Patry DG, Grand'Maison F, Myles ML, Paty DW, Selchen DH; Canadian MS Working Group.

Can J Neurol Sci. 2004 May;31(2):157-68. Review.

PMID:
15198439
7.

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.

Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD, Paty DW; IFNB Multiple Sclerosis Study Group.

Mult Scler. 2004 Apr;10(2):126-38.

PMID:
15124756
8.

Water content and myelin water fraction in multiple sclerosis. A T2 relaxation study.

Laule C, Vavasour IM, Moore GR, Oger J, Li DK, Paty DW, MacKay AL.

J Neurol. 2004 Mar;251(3):284-93.

PMID:
15015007
9.

Clinical relapses of multiple sclerosis are associated with 'novel' valleys in natural killer cell functional activity.

Kastrukoff LF, Lau A, Wee R, Zecchini D, White R, Paty DW.

J Neuroimmunol. 2003 Dec;145(1-2):103-14.

PMID:
14644036
10.

The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology. 2003 Nov 25;61(10):1332-8. Review.

PMID:
14638950
11.

Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis.

Laule C, Vavasour IM, Whittall KP, Oger J, Paty DW, Li DK, MacKay AL, Arnold DL.

J Neurol. 2003 Aug;250(8):924-31.

PMID:
12928910
12.
13.

Dendritic and synaptic pathology in experimental autoimmune encephalomyelitis.

Zhu B, Luo L, Moore GR, Paty DW, Cynader MS.

Am J Pathol. 2003 May;162(5):1639-50.

14.
15.

Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. 1993 [classical article].

Paty DW, Li DK; UBC MS/MRI Study Group and IFNB Multiple Sclerosis Study Group.

Neurology. 2001 Dec;57(12 Suppl 5):S10-5. No abstract available.

PMID:
11902589
16.

Normal-appearing white matter in multiple sclerosis has heterogeneous, diffusely prolonged T(2).

Whittall KP, MacKay AL, Li DK, Vavasour IM, Jones CK, Paty DW.

Magn Reson Med. 2002 Feb;47(2):403-8.

17.

The lesions of multiple sclerosis.

Paty DW, Arnold DL.

N Engl J Med. 2002 Jan 17;346(3):199-200. No abstract available.

PMID:
11796856
18.

Genetic susceptibility to MS: a second stage analysis in Canadian MS families.

Dyment DA, Willer CJ, Scott B, Armstrong H, Ligers A, Hillert J, Paty DW, Hashimoto S, Devonshire V, Hooge J, Kastrukoff L, Oger J, Metz L, Warren S, Hader W, Power C, Auty A, Nath A, Nelson R, Freedman M, Brunet D, Paulseth JE, Rice G, O'Connor P, Duquette P, Lapierre Y, Francis G, Bouchard JP, Murray TJ, Bhan V, Maxner C, Pryse-Phillips W, Stefanelli M, Sadovnick AD, Risch N, Ebers GC.

Neurogenetics. 2001 Jul;3(3):145-51.

PMID:
11523565
19.

Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS.

Ann Neurol. 2001 Jul;50(1):121-7.

PMID:
11456302
20.

Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis.

Liu Y, Zhu B, Luo L, Li P, Paty DW, Cynader MS.

Neuroreport. 2001 Jul 3;12(9):1841-5.

PMID:
11435909
21.

Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.

Li DK, Zhao GJ, Paty DW; University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group.

Neurology. 2001 Jun 12;56(11):1505-13.

PMID:
11402107
22.

T2 hyperintensities: findings and significance.

Li DK, Zhao G, Paty DW.

Neuroimaging Clin N Am. 2000 Nov;10(4):717-38 ,ix. Review.

PMID:
11359721
23.

A pathology-MRI study of the short-T2 component in formalin-fixed multiple sclerosis brain.

Moore GR, Leung E, MacKay AL, Vavasour IM, Whittall KP, Cover KS, Li DK, Hashimoto SA, Oger J, Sprinkle TJ, Paty DW.

Neurology. 2000 Nov 28;55(10):1506-10.

PMID:
11094105
24.

Ultrasound measurement of brain atrophy in multiple sclerosis.

Paty DW.

Arch Neurol. 2000 Sep;57(9):1264. No abstract available.

PMID:
11023451
25.

Defining the neurological basis of the Gulf War syndrome.

Rosenberg RN, Paty DW.

Arch Neurol. 2000 Sep;57(9):1263. No abstract available.

PMID:
10987891
26.
27.

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis.

Fazekas F, Barkhof F, Filippi M, Grossman RI, Li DK, McDonald WI, McFarland HF, Paty DW, Simon JH, Wolinsky JS, Miller DH.

Neurology. 1999 Aug 11;53(3):448-56. Review.

PMID:
10449103
29.

The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis.

Paty DW.

Neurology. 1999 Jul 22;53(2):437. No abstract available.

PMID:
10430451
30.

Axonal cytoskeleton changes in experimental optic neuritis.

Zhu B, Moore GR, Zwimpfer TJ, Kastrukoff LF, Dyer JK, Steeves JD, Paty DW, Cynader MS.

Brain Res. 1999 Apr 10;824(2):204-17.

PMID:
10196450
31.

Lesion load reproducibility and statistical sensitivity of clinical trials in multiple sclerosis.

Cover KS, Petkau J, Li DK, Paty DW.

Neurology. 1999 Jan 15;52(2):433-5. No abstract available.

PMID:
9932990
32.

Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.

Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW.

Neurology. 1999 Jan 15;52(2):351-9.

PMID:
9932956
33.

A comparison between magnetization transfer ratios and myelin water percentages in normals and multiple sclerosis patients.

Vavasour IM, Whittall KP, MacKay AL, Li DK, Vorobeychik G, Paty DW.

Magn Reson Med. 1998 Nov;40(5):763-8.

PMID:
9797161
34.

A role for natural killer cells in the immunopathogenesis of multiple sclerosis.

Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW.

J Neuroimmunol. 1998 Jun 15;86(2):123-33.

PMID:
9663557
35.
36.

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis.

Filippi M, Horsfield MA, Adèr HJ, Barkhof F, Bruzzi P, Evans A, Frank JA, Grossman RI, McFarland HF, Molyneux P, Paty DW, Simon J, Tofts PS, Wolinsky JS, Miller DH.

Ann Neurol. 1998 Apr;43(4):499-506.

PMID:
9546332
38.

Funding of drug treatment of multiple sclerosis should not be delayed.

Paty DW.

BMJ. 1997 Nov 1;315(7116):1160-1. No abstract available.

39.

MRI as a method to reveal in-vivo pathology in MS.

Paty DW.

J Neural Transm Suppl. 1997;49:211-7. Review.

PMID:
9266430
40.

Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. The MS Study Group.

Zhao GJ, Li DK, Wolinsky JS, Koopmans RA, Mietlowski W, Redekop WK, Riddehough A, Cover K, Paty DW.

J Neuroimaging. 1997 Jan;7(1):1-7.

PMID:
9038425
41.

In vivo measurement of T2 distributions and water contents in normal human brain.

Whittall KP, MacKay AL, Graeb DA, Nugent RA, Li DK, Paty DW.

Magn Reson Med. 1997 Jan;37(1):34-43.

PMID:
8978630
42.

Importance of magnetic resonance imaging and gadolinium enhancement.

Paty DW, Li DK.

Ann Neurol. 1996 Dec;40(6):951-3. No abstract available.

PMID:
9007110
43.

Guidelines for physicians with patients on IFN beta-1b: the use of an assay for neutralizing antibodies (NAB)

Paty DW, Goodkin D, Thompson A, Rice G.

Neurology. 1996 Oct;47(4):865-6. No abstract available.

PMID:
8857709
44.

A full genome search in multiple sclerosis.

Ebers GC, Kukay K, Bulman DE, Sadovnick AD, Rice G, Anderson C, Armstrong H, Cousin K, Bell RB, Hader W, Paty DW, Hashimoto S, Oger J, Duquette P, Warren S, Gray T, O'Connor P, Nath A, Auty A, Metz L, Francis G, Paulseth JE, Murray TJ, Pryse-Phillips W, Nelson R, Freedman M, Brunet D, Bouchard JP, Hinds D, Risch N.

Nat Genet. 1996 Aug;13(4):472-6.

PMID:
8696345
45.
46.

Depression and multiple sclerosis.

Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, Farquhar R, Hashimoto SA, Hooge J, Kastrukoff LF, Morrison W, Nelson J, Oger J, Paty DW.

Neurology. 1996 Mar;46(3):628-32.

PMID:
8618657
47.

Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial.

Rolak LA, Beck RW, Paty DW, Tourtellotte WW, Whitaker JN, Rudick RA.

Neurology. 1996 Feb;46(2):368-72.

PMID:
8614496
48.

Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force.

Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, Lublin FD, Paty DW, Reingold SC, Simon J.

Ann Neurol. 1996 Jan;39(1):6-16.

PMID:
8572668
49.

Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis.

Whitaker JN, Kachelhofer RD, Bradley EL, Burgard S, Layton BA, Reder AT, Morrison W, Zhao GJ, Paty DW.

Ann Neurol. 1995 Oct;38(4):625-32.

PMID:
7574459

Supplemental Content

Support Center